SCHEMBL24011342

SCHEMBL24011342

COc1ccc(CNC(=O)NC2CCC(C(=O)N3CCN(C(=O)c4ccccc4)CC3)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ MCHR1 Q99705 2/20 0.52
▸ HRH3 Q9Y5N1 1/20 0.52
▸ ACHE P22303 2/20 0.50
▸ BACE1 P56817 2/20 0.50
▸ ALDH1A1 P00352 4/20 0.49
▸ POLB P06746 2/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ MAPK8 P45983 1/20 0.48
▸ MAPK10 P53779 1/20 0.48
▸ EPHX2 P34913 1/20 0.48
▸ CDK1 P06493 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ BRAF P15056 1/20 0.47
▸ FGFR2 P21802 1/20 0.47
▸ FGFR4 P22455 1/20 0.47
▸ FGFR3 P22607 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24011198 0.90 NPC1 (0.64) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL26633914 0.90 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011436 0.87 SMN1; SMN2 (0.63) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011437 0.87 SMN1; SMN2 (0.63) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011481 0.85 NPC1 (0.68) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011062 0.84 SMN1; SMN2 (0.59) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011431 0.84 RAB9A (0.61) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011556 0.84 ACHE (0.49) SMN1; SMN2ACHEBACE1ALDH1A1POLB
SCHEMBL24011294 0.83 SMN1; SMN2 (0.58) NPC1RAB9ASMN1; SMN2MCHR1HRH3
SCHEMBL24011344 0.83 RAB9A (0.61) NPC1RAB9ASMN1; SMN2MCHR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
WO-2021226276-A2 NAMPT MODULATORS CYTOKINETICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT NPC1 128/4885RAB9A 814/4885SMN1; SMN2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback